The Global Council is a small and exclusive top-tier group of AI tech, academia, regulatory agency leaders, and the life sciences (pharma) industry, including Microsoft. The group’s remit is to pinpoint and showcase repeatable use cases that will shape the targeted use of next-generation artificial intelligence and machine learning (AI/ML) innovation, particularly in the form of GenAI.
The council’s main objectives, as set out in the charter, include creating a comprehensive and adaptable framework that facilitates the seamless integration of Generative AI in life sciences, ensuring its scalability and speed.
There will also be a patient-centric focus by developing strategies to consistently prioritize patient wellbeing, with a commitment to enhancing their experience and healthcare outcomes through Generative AI applications.
Legal and ethical requirements of GenAI
Regulatory compliance will involve establishing rigorous mechanisms to ensure full compliance with industry regulations and standards, ensuring that all Generative AI initiatives meet legal and ethical requirements.
Aman Wasan, CEO of ArisGlobal said: “The Launch of GenAI Council is part of our strategic focus on innovation. We have formed a dedicated focused group on innovation with a clear goal to identify valuable domain-specific use cases suitable for GenAI and bring the technology to life as part of the LifeSphere Platform, allowing customers to leverage advanced technology as part of our SaaS offerings.”
LifeSphere Safety is an end-to-end drug safety platform that helps hundreds of pharmacovigilance teams around the world save time and effort in drug safety.
Deployment of AI technologies
The council will also focus on responsible AI practices within the Life Sciences field, with an emphasis on transparency, privacy, security, fairness, and inclusivity throughout the development and deployment of AI technologies.
It will continuously evaluate and endorse diverse use cases for generative AI in life sciences that will include identifying opportunities to use AI for improved outcomes.
There will only be 12 companies appointed by invitation who will be offered a place for two senior representatives each to attend in-person council sessions. ArisGlobal says the closed-door approach will provide members with a unique opportunity to share freely insights into their latest ambitions and developments and learn first-hand from the experiences and ideas of their top-ranking peers.
Enormous potential to disrupt life sciences R&D processes
The council will meet quarterly with rotating global locations. The inaugural meeting in February, will take place in Princeton, New Jersey.
Elizabeth Smalley, VP of data & analytics at ArisGlobal, said: “GenAI and the use of Large Language Models to transform the interrogation and exploitation of diverse knowledge bases, offers enormous potential to disrupt Life Sciences R&D processes in a very positive way - to the direct benefit of patients as well as the wider healthcare ecosystem. The challenge is to apply this potential in specific, trailblazing ways that drive results and show the world what’s possible.
“GenAI technology is advancing at an incredible pace, and it’s this immense scope that the new Life Sciences Generative AI Council will now look to maximize and drive forward. Life Sciences leaders will need to proactively adopt and steer the application of these technologies to harness their considerable benefits while upholding a commitment to patient-centricity, regulatory compliance, and responsible AI standards, and the Council’s mission is to enable and ensure all of that.”